HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar

Executive Summary

Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)
Advertisement

Related Content

FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis
Progression-Free Survival Must Be Tied To Survival For Oncologic Approval
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication
Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication
Celgene Revlimid Post-Market Phase III Study To Explore Lower Dose
Oncology Drug Development Not Advanced By Non-Inferiority Trials – Pazdur
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS046710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel